Claims for Patent: 11,433,056

Summary for Patent: 11,433,056

Title:	Methods of treating gastrointestinal stromal tumors
Abstract:	The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
Inventor(s):	Soto; Rodrigo Ruiz (Waltham, MA), Rosen; Oliver (Waltham, MA), Pitman; Jama (Waltham, MA)
Assignee:	Deciphera Pharmaceuticals, LLC (Waltham, MA)
Application Number:	17/735,862
Patent Claims:	1. A method of treating a patient suffering from Grade 2 or Grade 3 myalgia while being administered 150 mg ripretinib daily for treatment of gastrointestinal stromal tumors, comprising: withholding administration of ripretinib for at least 7 days or until the patient has less than or equal to Grade 1 myalgia then administering to the patient 100 mg daily ripretinib for at least 28 days, if the patient is suffering from Grade 3 myalgia; or if the patient is suffering from Grade 2 myalgia, withholding administration of ripretinib until the patient has less than or equal to Grade 1 myalgia or baseline; if the patient recovers from the myalgia within 7 days of withholding administration, then administering to the patient 150 mg daily ripretinib, or if the patient has not recovered, then administering to the patient 100 mg daily ripretinib for at least 28 days. 2. A method of treating a patient suffering from Grade 3 myalgia while being administered 150 mg ripretinib daily or twice daily for treatment of gastrointestinal stromal tumors, comprising withholding administration of ripretinib for at least 7 days or until the patient has less than or equal to Grade 1 myalgia, then administering to the patient 100 mg daily ripretinib for at least 28 days. 3. A method of treating a patient suffering from Grade 2 myalgia while being administered 150 mg ripretinib daily for treatment of gastrointestinal stromal tumors comprising a) withholding administration of ripretinib until the patient has less than or equal to Grade 1 myalgia or baseline; b) if the patient recovers from the myalgia within 7 days of withholding administration, then administering to the patient 150 mg daily ripretinib or c) if the patient has not recovered, then administering to the patient 100 mg daily ripretinib for at least 28 days.